A Multi-Center, Open-Label Trial to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Subcutaneously Administered Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Participants with Systemic Lupus Erythematosus (SLE)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary)
Indications Systemic lupus erythematosus
Focus Pharmacokinetics
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

Most Recent Events

01 Mar 2024 Planned End Date changed from 15 Jan 2031 to 23 Apr 2027.
15 Nov 2023 Results assessing pharmacokinetics, pharmacodynamics, and safety of belimumab in pediatric patients with systemic lupus erythematosus presented at the ACR Convergence 2023.
05 Jun 2023 Planned End Date changed from 27 Jan 2031 to 15 Jan 2031.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight